The Week in Review: Huge China Hi-Tech Stimulus Rumored
According to reports, China will invest $1.7 trillion over the next five years in five strategic industries, including biotechnology, though the program has never been officially confirmed; Fosun Pharma received permission to offer up to $470 million of corporate bonds; Kunming Pharma will partner with Heilongjiang ZBD Pharma to develop a TCM used for blood disorders; Bayer has found a second life in China for a 17-year-old diabetes drug, Glucobay; Lilly remains worried about IP theft in China, even though the company is upping its investment in the PRC; and Tasly Pharma chose ICON to conduct a global Phase III trial of Tasly’s oral TCM treatment for angina. More details…. Stock Symbol: (SHA: 600196) (SHA: 600422) (XETRA: BAY) (NYSE: LLY) (SHA: 600535) (NSDQ: ICLR) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here